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Abstract 
Background: Brevican, neurocan, tenascin-C and tenascin-R are extracellular matrix 
(ECM) proteins that are mainly expressed in the brain. They play important roles in 
proliferation, migration and differentiation of neurons and other cell types in the brain. 
They are also expressed in various pathological conditions, including reactive gliosis. 
The aim of the study was to investigate if ECM protein concentrations in 
cerebrospinal fluid (CSF) are linked to the neurodegenerative process in Alzheimer’s 
disease (AD).  
Methods: Lumbar CSF samples from a non-AD control group (n=50) and a clinically 
diagnosed AD group (n=42), matched for age and gender, were analyzed using 
commercially available ELISAs detecting ECM proteins. Mann-Whitney U test were 
used to examine group differences, while Spearman’s rho test was used for 
correlations.  
Results: Brevican, neurocan and tenascin-R concentrations in AD patients did not 
differ compared to healthy controls.  
Conclusions: ECM proteins do not reflect AD-pathology in CSF.  
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Introduction  
Alzheimer’s disease (AD) is an irreversible and progressive brain disorder, and the 
most common form of dementia. The risk of AD is clearly correlated with increasing 
age and, clinically, the disease is characterized by memory loss and other forms of 
cognitive impairment (1). Almost 50 million people worldwide are affected by AD and 
this number is growing (2). Treatments for AD symptoms are available (3), however 
there is still no approved disease-modifying drug. Major pathological hallmarks of AD 
include extracellular senile plaques (SPs) formed by amyloid β (Aβ) fibrils and 
intracellular neurofibrillary tangles (NFTs) formed by hyperphosporylated tau protein 
(1). There is a worldwide effort to find early biomarkers for the disease, which detect 
pathological changes before symptoms are noticeable. There are three protein 
biomarkers in cerebrospinal fluid (CSF), which can be used to detect AD pathologies: 
total tau (t-tau), phosphorylated tau (p-tau) and the 42 amino acid form of Aβ (4). 
These biomarkers are now part of the research diagnostic criteria for AD (5, 6) but 
there is still a need for new biomarkers that can be used for example in differential 
diagnostics and for prognosis.  
Extracellular matrix (ECM) components are believed to contribute to AD progression. 
The function of ECM is to provide physical support to surrounding cells as well as to 
regulate intercellular communication (7); its major components are proteoglycans and 
glycoproteins. They play important role in cell adhesion, migration, neurite outgrowth 
and guidance (8). Brevican and neurocan are nervous-specific chondroitin sulphate 
proteoglycans (CSPG) (9), while tenascin-C and tenascin-R are large glycoproteins, 
where tenascin-C is expressed in connective tissues (10), whereas tenascin-R is 
abundant in nervous tissue (9). Brevican, neurocan and both tenascins are 
expressed by neuronal and glial cells (9, 11-13). As a response to the production of 
cytokines by activated microglia, astrocytes secrete proteoglycans around the areas 
of CNS tissue damage, leading to the formation of glial scars. This structure is not 
only a barrier to axonal regeneration, but it also inhibits the spread of the damage to 
other areas (14). Glial scars mainly consist of CSPGs and tenascin-R (15). Tenascin-
C is also upregulated in inflammation (16) and upon microglial activation in AD (ref), 
where Aβ plaques and neurofibrillary tangles are surrounded by reactive astrocytes 
(14).  
The aim of the study was to investigate if there are any alterations in the 
concentrations of these ECM proteins in CSF from AD patients compared to healthy 
controls. 
 
Materials and methods 
The study was conducted according to the Helsinki Declaration and approved by the 
regional ethical board in Lund (#2016/1053). 
The study involved 42 AD patients and 50 healthy controls (Table 1). AD patients had 
abnormal core AD CSF biomarker (Aβ42, t-tau and p-tau) levels, while controls had 
normal levels. One AD patient lacked CSF AD biomarker results. The two groups 
were age- and gender-matched. CSF samples were collected by lumbar puncture 
procedures. Mini Mental State Examination (MMSE) was used to measure cognitive 
impairment.  
Brevican, neurocan, tenascin-C and tenascin-R concentrations in CSF were measured 
using sandwich ELISA (RayBiotech, Norcross, GA, USA). The dilution factors were: 
1:400 for brevican, 1:10 for neurocan and 1:2 for both tenascins. Quality control CSF 
pools were run at the beginning and the end of each assay to evaluate possible inter 
and intra alteration. The coefficients of variation (CVs) for the repeatability were below 
11% and CVs for the intermediate precision measurements were below 19%. The CSF 
samples were measured in singlicates due to volume limitations. 
Because most of the CSF results were non-normally distributed, group comparisons 
were made using the Mann-Whitney U test. Associations between variables were 
reported by Spearman’s rank correlation coefficient. The analyses were performed 
using SPSS software, version 25 or GraphPad Prism, version 7. All tests were two-
sided and statistical significance was defined as p ≤ 0.05. 
 
Results 
Patient demographics together with biomarker concentrations are shown in Table 1. 
Brevican, neurocan, tenascin-C and tenascin-R concentrations did not differ between 
AD and control groups (Fig.1). Brevican, neurocan and tenascin-R values correlated 
with each other in the control and AD groups separately as well as in the two groups 
combined (rho=0.68-0.77, p<0.05). Neurocan correlated with Aβ40 (rho=0.60, 
p<0.05) in both groups, whilst its correlation with t-tau was only observed in the 
control group (rho=0.63, p<0.05). CSF ECM protein concentrations were similar in 
men and women in the control group, however tenascin-C and tenascin-R 
concentrations were significantly higher in women than in men in the AD group 
(p=0.02 for both biomarkers, Fig.2).  
 
Discussion 
Previous studies using in house (non-commercial) assays for the ECM proteins and 
small samples were inconclusive (data not shown) and here results from larger and 
well-characterized AD-control cohorts is presented. The results indicate that CSF 
concentrations of brevican, neurocan, tenascin-C and tenascin-R are not changed in 
AD even though several studies suggest that ECM proteins are involved in AD 
pathophysiology. For example, CSPGs have been found in SPs (17) and they are 
known to inhibit the degradation of SPs and contribute to their persistence and even 
propagation in AD (8). CSPGs bind to fibrillar Aβ and inhibit its proteolytic 
degradation (18). They inhibit the removal of Aβ deposits by microglia (19) and they 
promote Aβ aggregation into insoluble amyloid fibrils (20).  It has also been shown 
that Aβ aggregation alters the structure and proteolytic cleavage of brevican (21). 
Moreover, matrix metalloproteinases that cleave brevican lost their activity in the 
same model, consequently reducing the amount of an N-terminal proteolytic fragment 
of brevican (21). Aβ accumulation was observed to upregulate neurocan expression 
(22). Tenascin-C was found to form extracellular deposits around Aβ plaques (23) 
and its transcription was upregulated in response to Aβ exposure (16, 23). 
Estrogens are thought to play a role in gender difference observed in many 
neurological diseases, including AD (24). Previous studies reported that women are 
at increased risk of developing AD (24, 25), which might be associated with a 
reduction of brain estrogen levels in postmenopausal women compared to age-
matched men (24). AD pathogenesis strongly interacts with immunological 
mechanisms in the brain and frequency of complications related to inflammatory 
conditions are greater in women (26, 27). Our observation of increased tenascin 
concentrations in women could potentially reflect these sex differences, although 
more studies are needed to draw any firm conclusions on this.   
 
In conclusion, strong correlations between CSF concentrations of brevican, neurocan 
and tenascin-R in both AD and control groups suggest that these ECM proteins 
reflect the same neurophysiological processes occurring in the CNS, whilst the lack 
of AD vs. control group differences speak against any strong association with the 
pathological process of AD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table1. Demographic and biomarkers 
  
Characteristic AD 
(n=42) 
Controls 
(n=50) 
Gender, n (%) Male 
Female 
13 (31%) 
29 (69%) 
16 (32%) 
34 (68%) 
Age, median (IQR) 75 (11.8) 75 (9.75) 
Protein concentration, median (IQR) [ng/ml] 
ECM proteins Brevican  466 (250) 521 (216) 
Neurocan 37.6 (14.4) 38.9 (13.4) 
Tenascin-C 0.118 (0.0536) 0.102 (0.0638) 
Tenascin-R 1.78 (0.828) 1.82 (0.748) 
AD biomarkers Aβ40 6.29 (2.50) 6.33 (2.56) 
Aβ42 0.411 (0.156) 0.789 (0.461) 
T-tau 0.606 (0.247) 0.319 (0.131) 
P-tau 0.106 (0.0571) 0.0431 (0.0205) 
 
 
 
 
 
 
 
 
 
  
Fig.1 ECM proteins in CSF from AD patients compared to healthy controls. 
Represented as median with interquartile range. 
 
 
 
 
 
 Fig.2 Tenascin-C (A) and tenascin-R (B) protein concentrations in female and male 
groups of AD patients. 
Represented as median with interquartile range. 
Significance: *= p ≤ 0.05 
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